Boya Bio-Pharmaceutical Group secures tetanus immunoglobulin drug registration

Boya Bio-Pharmaceutical Group Co., Ltd. recently obtained a drug registration certificate for human tetanus immunoglobulin from the National Medical Products Administration. This approval follows a cumulative R&D investment of CNY 9.75 million and is expected to enrich the company's product line and boost R&D initiatives, though it is not anticipated to materially impact the 2025 operating performance. The drug is an injectable with 250IU (2.5ml) of tetanus antibody per bottle.

The company's board of directors approved the co-option of Li Changqing as an independent director. Li Changqing is a professor and director at the Chinese Academy of Medical Sciences Institute of Blood Transfusion, with no prior affiliation with the company and no shares held. This appointment, along with the independent director's annual subsidy of CNY 200,000 (pre-tax), awaits shareholder approval.

Several other companies, including Hualan Biological Engineering Inc., Guangdong Shuanglin Bio-pharmaceutical Co., Ltd., and Chengdu Rongsheng Pharmaceuticals Co., Ltd., already have approved human tetanus immunoglobulin products in China. Boya Bio-Pharmaceutical Group's new registration increases its competitive standing in the domestic market.